104 related articles for article (PubMed ID: 8635866)
1. Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line.
Abbaszadegan MR; Foley NE; Gleason-Guzman MC; Dalton WS
Int J Cancer; 1996 May; 66(4):506-14. PubMed ID: 8635866
[TBL] [Abstract][Full Text] [Related]
2. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.
Abbaszadegan MR; Cress AE; Futscher BW; Bellamy WT; Dalton WS
Cancer Res; 1996 Dec; 56(23):5435-42. PubMed ID: 8968098
[TBL] [Abstract][Full Text] [Related]
3. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance.
Futscher BW; Foley NE; Gleason-Guzman MC; Meltzer PS; Sullivan DM; Dalton WS
Int J Cancer; 1996 May; 66(4):520-5. PubMed ID: 8635868
[TBL] [Abstract][Full Text] [Related]
4. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage.
Bellamy WT; Dalton WS; Kailey JM; Gleason MC; McCloskey TM; Dorr RT; Alberts DS
Cancer Res; 1988 Nov; 48(22):6365-70. PubMed ID: 3180056
[TBL] [Abstract][Full Text] [Related]
5. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
6. Major contribution of the multidrug transporter P-glycoprotein to reduced susceptibility of poly(ADP-ribose) polymerase-1 knock-out cells to doxorubicin action.
Wesierska-Gadek J
J Cell Biochem; 2005 Aug; 95(5):1012-28. PubMed ID: 15861398
[TBL] [Abstract][Full Text] [Related]
7. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
Döppenschmitt S; Langguth P; Regårdh CG; Andersson TB; Hilgendorf C; Spahn-Langguth H
J Pharmacol Exp Ther; 1999 Jan; 288(1):348-57. PubMed ID: 9862789
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.
Chen YL; Yang TY; Chen KC; Wu CL; Hsu SL; Hsueh CM
Cell Oncol (Dordr); 2016 Oct; 39(5):411-433. PubMed ID: 27306525
[TBL] [Abstract][Full Text] [Related]
9. BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells.
Liu Z; Lheureux F; Pouliot JF; Heckel A; Bamberger U; Georges E
Mol Pharmacol; 1996 Sep; 50(3):482-92. PubMed ID: 8794885
[TBL] [Abstract][Full Text] [Related]
10. Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody.
Tong AW; Lee J; Wang RM; Dalton WS; Tsuruo T; Fay JW; Stone MJ
Cancer Res; 1989 Sep; 49(17):4829-34. PubMed ID: 2569359
[TBL] [Abstract][Full Text] [Related]
11. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
12. Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid.
Majumder S; Dutta P; Mukherjee P; Datta ER; Efferth T; Bhattacharya S; Choudhuri SK
Cancer Lett; 2006 Nov; 244(1):16-23. PubMed ID: 16410038
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A
Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233
[TBL] [Abstract][Full Text] [Related]
14. [MDR (Multiple Drug Resistant) type of resistance to chemotherapy in clinical practice].
Oudard S; Marie JP; Pujade Lauraine E
Bull Cancer; 1996 Aug; 83(8):609-18. PubMed ID: 8869040
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability.
Drori S; Eytan GD; Assaraf YG
Eur J Biochem; 1995 Mar; 228(3):1020-9. PubMed ID: 7737146
[TBL] [Abstract][Full Text] [Related]
16. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
[TBL] [Abstract][Full Text] [Related]
17. Medroxyprogesterone-acetate reverses the MDR phenotype of the CG5-doxorubicin resistant human breast cancer cell line.
Zibera C; Gibelli N; Maestri L; Della Cuna GR
Anticancer Res; 1995; 15(3):745-9. PubMed ID: 7645952
[TBL] [Abstract][Full Text] [Related]
18. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
19. Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells.
Limtrakul P; Siwanon S; Yodkeeree S; Duangrat C
Phytomedicine; 2007 Jun; 14(6):381-9. PubMed ID: 17467965
[TBL] [Abstract][Full Text] [Related]
20. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.
Theyer G; Schirmböck M; Thalhammer T; Sherwood ER; Baumgartner G; Hamilton G
J Urol; 1993 Nov; 150(5 Pt 1):1544-7. PubMed ID: 8105110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
